Literature DB >> 25765878

Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma.

Andrew S Brohl1, Li Li2, Vaagn Andikyan2, Sarah G Običan2, Angela Cioffi2, Ke Hao2, Joel T Dudley2, Charles Ascher-Walsh2, Andrew Kasarskis2, Robert G Maki2.   

Abstract

BACKGROUND: Estimates of unexpected uterine sarcoma following surgery for presumed benign leiomyoma that use age-stratification are lacking. PATIENTS AND METHODS: A retrospective cohort of 2,075 patients that had undergone myomectomy was evaluated to determine the case incidence of unexpected uterine sarcoma. An aggregate risk estimate was generated using a meta-analysis of similar studies plus our data. Database-derived age distributions of the incidence rates of uterine sarcoma and uterine leiomyoma surgery were used to stratify risk by age.
RESULTS: Of 2,075 patients in our retrospective cohort, 6 were diagnosed with uterine sarcoma. Our meta-analysis revealed 8 studies from 1980 to 2014. Combined with our study, 18 cases of leiomyosarcoma are reported in 10,120 patients, for an aggregate risk of 1.78 per 1,000 (95% confidence interval [CI]: 1.1-2.8) or 1 in 562. Eight cases of other uterine sarcomas were reported in 6,889 patients, for an aggregate risk of 1.16 per 1,000 (95% CI: 0.5-4.9) or 1 in 861. The summation of these risks gives an overall risk of uterine sarcoma of 2.94 per 1,000 (95% CI: 1.8-4.1) or 1 in 340. After stratification by age, we predict the risk of uterine sarcoma to range from a peak of 10.1 cases per 1,000, or 1 in 98, for patients aged 75-79 years to <1 case per 500 for patients aged <30 years.
CONCLUSION: The risk of unexpected uterine sarcoma varies significantly across age groups. Our age-stratified predictive model should be incorporated to more accurately counsel patients and to assist in providing guidelines for the surgical technique for leiomyoma. ©AlphaMed Press.

Entities:  

Keywords:  Endometrial stromal sarcoma; Hysterectomy; Leiomyoma; Leiomyosarcoma; Uterine myomectomy

Mesh:

Year:  2015        PMID: 25765878      PMCID: PMC4391766          DOI: 10.1634/theoncologist.2014-0361

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  16 in total

1.  Routine hysterectomy for large asymptomatic uterine leiomyomata: a reappraisal.

Authors:  R C Reiter; P L Wagner; J C Gambone
Journal:  Obstet Gynecol       Date:  1992-04       Impact factor: 7.661

2.  Gynecological malignant neoplasias diagnosed after hysterectomy performed for leiomyoma in a university hospital.

Authors:  T S F Kamikabeya; R M Etchebehere; R S Nomelini; E F C Murta
Journal:  Eur J Gynaecol Oncol       Date:  2010       Impact factor: 0.196

3.  Perioperative complication rate in 1706 patients after a standardized laparoscopic supracervical hysterectomy technique.

Authors:  Bernd Bojahr; Detlef Raatz; Georg Schonleber; Christine Abri; Ralf Ohlinger
Journal:  J Minim Invasive Gynecol       Date:  2006 May-Jun       Impact factor: 4.137

4.  Uterine leiomyosarcoma: does the primary surgical procedure matter?

Authors:  Tamar Perri; Jacob Korach; Siegal Sadetzki; Bernice Oberman; Eddie Fridman; Gilad Ben-Baruch
Journal:  Int J Gynecol Cancer       Date:  2009-02       Impact factor: 3.437

5.  Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma.

Authors:  W H Parker; Y S Fu; J S Berek
Journal:  Obstet Gynecol       Date:  1994-03       Impact factor: 7.661

6.  Laparoscopic myomectomy: do size, number, and location of the myomas form limiting factors for laparoscopic myomectomy?

Authors:  Rakesh Sinha; Aparna Hegde; Chaitali Mahajan; Nandita Dubey; Meenakshi Sundaram
Journal:  J Minim Invasive Gynecol       Date:  2008 May-Jun       Impact factor: 4.137

7.  Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas.

Authors:  S Leibsohn; G d'Ablaing; D R Mishell; J B Schlaerth
Journal:  Am J Obstet Gynecol       Date:  1990-04       Impact factor: 8.661

8.  Risk factors for surgically removed fibroids in a large cohort of teachers.

Authors:  Claire Templeman; Sarah F Marshall; Christina A Clarke; Katherine DeLellis Henderson; Joan Largent; Susan Neuhausen; Peggy Reynolds; Giske Ursin; Leslie Bernstein
Journal:  Fertil Steril       Date:  2008-11-18       Impact factor: 7.329

9.  Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.

Authors:  Sandra E Brooks; Min Zhan; Timothy Cote; Claudia R Baquet
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

10.  Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients.

Authors:  P Morice; A Rodriguez; A Rey; P Pautier; D Atallah; C Genestie; C Pomel; C Lhommé; C Haie-Meder; P Duvillard; D Castaigne
Journal:  Eur J Gynaecol Oncol       Date:  2003       Impact factor: 0.196

View more
  16 in total

1.  YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy.

Authors:  Matthew L Hemming; Andrew J Wagner; Marisa R Nucci; Sarah Chiang; Lu Wang; Martee L Hensley; Suzanne George
Journal:  Gynecol Oncol       Date:  2017-04-05       Impact factor: 5.482

Review 2.  Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions.

Authors:  Klaudia Żak; Bartłomiej Zaremba; Alicja Rajtak; Jan Kotarski; Frédéric Amant; Marcin Bobiński
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.575

3.  Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study.

Authors:  Francesco Multinu; Jvan Casarin; Lucia Tortorella; Yajue Huang; Amy Weaver; Stefano Angioni; Gian Benedetto Melis; Andrea Mariani; Elizabeth A Stewart; Shannon K Laughlin-Tommaso
Journal:  Am J Obstet Gynecol       Date:  2018-11-14       Impact factor: 8.661

4.  Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019).

Authors:  Dominik Denschlag; Sven Ackermann; Marco Johannes Battista; Wolfgang Cremer; Gerlinde Egerer; Markus Follmann; Heidemarie Haas; Philipp Harter; Simone Hettmer; Lars-Christian Horn; Ingolf Juhasz-Boess; Karin Kast; Günter Köhler; Thomas Kröncke; Katja Lindel; Peter Mallmann; Regine Meyer-Steinacker; Alexander Mustea; Edgar Petru; Peter Reichardt; Dietmar Schmidt; Hans-Georg Strauss; Clemens Tempfer; Falk Thiel; Uwe Ulrich; Thomas Vogl; Dirk Vordermark; Paul Gass; Matthias W Beckmann
Journal:  Geburtshilfe Frauenheilkd       Date:  2019-10-22       Impact factor: 2.915

5.  Incidence of occult leiomyosarcoma in presumed morcellation cases: a database study.

Authors:  Ana M Rodriguez; Mehmet R Asoglu; Muhammet Erdal Sak; Alai Tan; Mostafa A Borahay; Gokhan S Kilic
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2015-11-28       Impact factor: 2.831

Review 6.  UK guidelines for the management of soft tissue sarcomas.

Authors:  Adam Dangoor; Beatrice Seddon; Craig Gerrand; Robert Grimer; Jeremy Whelan; Ian Judson
Journal:  Clin Sarcoma Res       Date:  2016-11-15

7.  Survey among ESGE members on leiomyosarcoma morcellation incidence.

Authors:  Hans Brölmann; Rudi Leon DeWilde; Peter O'Donovan; Elina Symeonidou; Rudi Campo; Vasilios Tanos
Journal:  Gynecol Surg       Date:  2017-12-04

8.  Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma.

Authors:  Rosanne M Kho; Vrunda B Desai; Peter E Schwartz; Jason D Wright; Cary P Gross; Lindsey M Hutchison; Francis P Boscoe; Haiqun Lin; Xiao Xu
Journal:  J Minim Invasive Gynecol       Date:  2021-07-13       Impact factor: 4.137

Review 9.  Abnormal uterine bleeding.

Authors:  Lucy Whitaker; Hilary O D Critchley
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2015-11-25       Impact factor: 5.237

10.  Incidence and clinical characteristics of unexpected uterine sarcoma after hysterectomy and myomectomy for uterine fibroids: a retrospective study of 10,248 cases.

Authors:  Wan-Cheng Zhao; Fang-Fang Bi; Da Li; Qing Yang
Journal:  Onco Targets Ther       Date:  2015-10-15       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.